29th Sep 2016 11:35
LONDON (Alliance News) - AstraZeneca PLC said Thursday the US Food and Drug Administration has approved a blood-based companion diagnostic for non-small cell lung cancer treatment Tagrisso.
The companion diagnostic, the cobas EGFR Mutation Test v2, was developed by Roche Molecular Systems Inc.
AstraZeneca said the approval provides a new, non-invasive option to identify patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer, ensuring that those patients who may not be suitable for biopsy procedures have an opportunity to be tested.
Shares in AstraZeneca were down 0.6% at 5,091.00 pence Thursday afternoon.
Copyright RTT News/dpa-AFX
Related Shares:
Astrazeneca